Methylene blue (MB) is a widely studied agent currently under investigation for its properties relating to photodynamic therapy (PDT). Recent studies have demonstrated that MB exhibits profound phototoxicity affecting a variety of tumor cell lines. However, the mechanistic explanation for methylene-blue-mediated photodynamic therapy (MB-PDT) in the context of melanoma therapy is still obscure. In the present study, B16F1 melanoma cells were treated by MB-PDT under different conditions, and thereafter subjected to cell viability detection assays. MB-PDT could induce intense apoptotic cell death through a series of steps beginning with the photochemical generation of reactive oxygen species that activate the caspase-9/ caspase-3 apoptosis pathway. Blocking activation of caspase-3 and induction of oxidative stress by caspase inhibitor and by glutathione, respectively, markedly reduced apoptotic cell death in vitro. P hotodynamic therapy (PDT) involves the systemic or local administration of a tumor-localizing photosensitizer followed by irradiation of the targeted lesion with light of the appropriate wavelength. This multistep procedure initiates a complex photochemical reaction to generate reactive oxygen species (ROS). The cytotoxic products generated by PDT trigger a cascade of molecular events that lead to apoptosis and/or necrosis of cells responsible for tumor destruction.(1,2) Therefore PDT is considered to be a promising technology approved as an alternative treatment for a diverse array of cancers, such as cervical cancer, oesophageal cancer, head and neck cancer and skin malignancies. (3,4) Melanoma is a cancer developing from malignant transformation of melanocytes, the pigment-producing cells that are found predominantly in the skin.(5) It is worth noting that melanocytes originating from highly motile cells have enhanced survival properties and are relatively resistant to drug-induced apoptosis and chemotherapy.(6,7) Previous studies have investigated the application of PDT with several photosensitizers, such as lutetium texaphyrin, (8) chlorin e 6 , (9) and 5-aminolaevulinic acid,to induce cell death of melanocytes in vivo and in vitro. Although initial treatment responses after PDT are routinely positive; the difficulty in achieving good light excitation of these sensitizers and ethical considerations concerning the aggressiveness of the disease hinder the development of the application of PDT for treating melanomas. Methylene blue (MB), from the phenothiazinium family, is a photosensitizer which has excellent photochemical properties. MB is well known to have a high quantum yield of intersystem crossing and singlet oxygen ( 1 O 2 ) generation, and can produce radical species in the presence of reducing agents.(11,12) Importantly, MB possesses exceptional affinity to melanocyteproduced melanin, which contributes to selective absorption of this compound by cutaneous melanomas.(13) Compared with other photosensitizers, MB showed enhanced penetration efficiency into melanoma cells. It has been reported ...